Every Form 4 that Outlook Therapeutics, Inc. (OTLK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OTLK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OTLK filings page.
Outlook Therapeutics, Inc. (OTLK) reported that its Chief Financial Officer, Kevin Michael Lundquist, received a grant of 500,000 employee stock options on September 1, 2026. The options have an exercise price of $0.63 per share and expire on September 1, 2036. The grant was made as an inducement to his employment under Nasdaq Listing Rule 5635(c)(4) and vests 25% on September 1, 2027, with the remainder vesting in equal monthly installments over the following three years, subject to his continuous service.
Outlook Therapeutics, Inc. director and Chief Executive Officer Robert Charles Jahr purchased 151,515 shares of common stock and 151,515 accompanying warrants on August 14, 2026 in an underwritten public offering at a combined public offering price of $0.99 per share and warrant. The warrants are exercisable immediately at $1.10 per share and expire on August 14, 2031. Following these transactions, Jahr holds 151,515 common shares and 151,515 warrants directly.
Outlook Therapeutics, Inc. insider GMS Ventures & Investments, associated with director and 10% owner Ghiath M. Sukhtian, participated in an underwritten public offering on August 12, 2026. GMS Ventures purchased 2,525,252 shares of common stock at $0.99 per share and received accompanying warrants to purchase 2,525,252 shares of common stock at an exercise price of $1.10 per share. The warrants were issued for $0.00 as part of the combined public offering price, are exercisable immediately, and expire on August 14, 2031 subject to a beneficial ownership limitation. Following the stock purchase, GMS Ventures held 24,617,320 shares of Outlook Therapeutics common stock indirectly reported for Sukhtian, with both reporting persons disclaiming beneficial ownership beyond their pecuniary interest.
Outlook Therapeutics, Inc. director and Chief Financial Officer Lawrence A. Kenyon reported open-market-style purchases tied to an underwritten public offering on August 14, 2026. He acquired 101,010 shares of common stock plus accompanying warrants to purchase another 101,010 shares, for a combined public offering price of $0.99 per share and warrant. The warrants are immediately exercisable at $1.10 per share and expire on August 14, 2031. Following the stock purchase, he held 106,956 common shares directly.
Outlook Therapeutics director Faisal Ghiath Sukhtian purchased 95,398 shares of common stock on July 29, 2026 at 1.0482 per share in an open-market or private transaction. After this buy, he directly owns 220,972 common shares. The transaction was not reported as made under a Rule 10b5-1 trading plan.
Outlook Therapeutics, Inc. reported that Chief Financial Officer Lawrence A. Kenyon received a grant of 210,078 stock options on July 21, 2026 under its 2024 Equity Incentive Plan. Each option covers one share of common stock at an exercise price of 1.4304 per share, vests in full on July 21, 2027, and expires on July 21, 2036, conditional on his continued service.
Outlook Therapeutics, Inc. reports that Chief Executive Officer Robert Charles Jahr received a grant of stock options covering 100,000 shares of common stock at an exercise price of $1.4304 per share. Granted on July 21, 2026 under the 2024 Equity Incentive Plan, the options vest in full on July 21, 2027 and expire on July 21, 2036, leaving him with 100,000 options held directly.
Outlook Therapeutics director Yezan Munther Haddadin bought 29,000 shares of Common Stock in an open-market purchase. The shares were acquired at an average price of $0.8326 per share. Following this transaction, he directly holds a total of 66,167 Outlook Therapeutics shares.
Outlook Therapeutics received a new investment from GMS Ventures & Investments, which bought 8,539,709 shares of common stock at $0.5855 per share in a registered direct offering for a total purchase price of about $5.0 million. Following this purchase, GMS Ventures reported indirect ownership of 22,092,068 common shares.
The filing also shows amendments to multiple warrant series held by GMS Ventures. Existing warrants with exercise prices of $2.26 and $1.40 per share were cancelled and replaced with new warrants covering the same share amounts at a reduced exercise price of $0.5855 per share, with expirations in 2030. The transactions are reported as cancellations of old warrants and acquisitions of new ones rather than exercises.
All securities are held of record by GMS Ventures. Ghiath M. Sukhtian controls GMS Ventures and may be deemed to share voting and investment power, but the reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest.
Outlook Therapeutics, Inc. director Sukhtian Faisal Ghiath reported an open-market purchase of 122,174 shares of Common Stock at an average price of $0.4093 per share. Following this transaction, he directly owns a total of 125,574 Common Stock shares.
Outlook Therapeutics, Inc. director Yezan Munther Haddadin reported an open-market purchase of the company’s Common Stock. On May 26, 2026, he bought 34,000 shares at $0.44 per share. Following this transaction, he directly owns 37,167 shares of Outlook Therapeutics common stock.
Outlook Therapeutics director buys shares on the open market. Director Randy H. Thurman purchased 5,000 shares of Outlook Therapeutics common stock in an open-market transaction at $0.429 per share. Following this trade, he directly holds a total of 5,593 shares of the company.
Outlook Therapeutics director Kurt J. Hilzinger increased his personal stake by buying 400,000 shares of Common Stock in an open-market purchase. The shares were acquired at an average price of $0.4413 per share. Following this transaction, he directly owns 423,655 shares of Outlook Therapeutics common stock.